Awaiting development: Guidance and quality standards
Showing 11 to 11 of 11
| Title | Type |
|---|---|
| Teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments including an anti-CD38 antibody and lenalidomide [ID6628] | Technology appraisal guidance |